Personalized GIP + GLP-1 targets two pathways (GIP and GLP-1), which can provide broader metabolic support for some people
The concept of exploring the therapeutic utility of anti-diabetic agents in both AD and PD came from multiple independent studies showing that diabetes is a risk factor for these diseases 2,3
Social media often highlights extreme or immediate cases, but for most people, true progress unfolds gradually
We accept all major insurance plans and our team manages the entire prior authorization procedure for access to weight loss medications
Clinically, retatrutide has been demonstrated to decrease visceral fat mass without sacrificing lean muscle, which is crucial for metabolic health and mitigating obesity-related risks
Combining adequate protein intake (1.2 to 1.6 g/kg daily), consistent resistance training, and targeted therapies like peptide therapy can protect your muscle while maximizing fat loss